Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

Women's Health Series: Is There Change Ahead for the Female Infertility Market?

Published by: Decision Resources

Published: Aug. 25, 2008 - 25 Pages


Table of Contents


Executive Summary

Strategic Considerations

Stakeholder Implications

Introduction

Overview of Female Infertility

Normal Menstrual Cycle and Fertility

Causes of Infertility

Anovulation

Endometriosis

Tubal Disorders

Current Therapies for Female Infertility

Sanofi -Aventis’s Clomid

Follicle-Stimulating Hormones

Ferring Pharmaceuticals’ Bravelle

Schering-Plough’s Follistim AQ

Ferring Pharmaceuticals’ Repronex

Schering-Plough’s Ganirelix

Merck Serono’s Ovidrel

Ferring Pharmaceuticals’ Endometrin

Surgical Interventions

Medical Practice

Anovulation

Endometriosis

Unexplained Infertility

Emerging Therapies to Treat Female Infertility

Outlook for the Female Infertility Market

Tables

1. Approved Agents for the Treatment of Female Infertility

2. Emerging Therapies for the Treatment of Female Infertility

Figures

1. Estimated Percentages of Infertility Cases, by Type

2. Percentage of Infertility Patients, by Age Range, Seeking Treatment from an Obstetrician/Gynecologist

3. Survey Question: Of patients whose cause of infertility is endometriosis, what percentage fall into the mild, moderate, and severe categories?

4. Survey Question: Please rank your top three agents for follicle stimulation prior to an assisted reproduction procedure

5. Survey Question: In what percentage of your patients who receive assisted reproduction procedures do you prescribe luteal phase support medications?

6. Specialist Estimates of Distribution of Types of Assisted Reproduction Procedures

7. Survey Question: At what point do you recommend that your patients who are trying to conceive seek fertility treatments?

8. Specialists’ Choices for First-, Second-, and Third-Line Therapies for the Treatment of Anovulation

9. Specialists’ Choices for First- and Second-Line Therapies for the Treatment of Infertility Caused by Mild Endometriosis

10. Specialists’ Choices for First- and Second-Line Therapies for the Treatment of Infertility Caused by Moderate Endometriosis

11. Specialists’ Choices for First- and Second-Line Therapies for the Treatment of Infertility Caused by Severe Endometriosis

12. Specialists’ Choices for First-, Second-, and Third-Line Therapies for the Treatment of Unexplained Fertility

Abstract

Introduction

Mounting evidence that a growing number of women are choosing to delay childbirth into their mid-tolate thirties highlights a significant opportunity for new and efficacious infertility treatments. Despite the increasing level of need, the treatment of infertility has not changed significantly over the past several decades because drug developers have been put off by the relatively small market, reimbursement concerns, and the efficacy of existing treatment. However, there is room in this market for an agent that can address the infertility issues of the moderately high percentage of women who have failed existing treatments.

Get the Answers You Need to Shape Your Strategy
  • It has long been established that fertility in women drops after age 35; however, an increasing number of women are waiting until this age to have children. What are the primary causes of infertility? What are the age ranges most highly affected by infertility, according to surveyed specialists?
  • The newest agent for the treatment of infertility was approved in 2007; however, the most commonly prescribed agent is several decades old. What are the prescribing patterns of specialists for the various causes of infertility? What are the overall success rates of infertility treatments? What reimbursement policies are in place for infertility treatments?
  • A significant percentage of women who undergo fertility treatments still fail to conceive.What emerging agents are being developed for infertility? What benefits do these agents offer over existing agents? What is the likelihood that these agents will establish a position in the infertility market?
Scope
  • Overview of infertility: normal menstrual cycle and fertility, causes of infertility.
  • Currently approved treatments for infertility: clomiphene citrate, follicle-stimulating hormones, human menopausal hormones, Schering-Plough’s Ganirelix, Merck Serono’s Ovidrel.
  • Medical practice: U.S. specialists surveyed to determine current prescribing patterns for various types of infertility.
  • Emerging treatments: a review of the infertility pipeline, including the lead agent, Schering- Plough’s corifollitropin alfa.
  • Outlook for the infertility market: current market drivers and constraints, adoption of emerging agents.
  • Women’s Health Series: In 2007, the market for women’s reproductive health exceeded $23 billion worldwide. In the Women’s Health Series, we examine three specific markets, focusing on areas of unmet need and the best marketing strategies to ensure adoption of a new agent. We will provide insight from a variety of thought leaders on the current state of disease treatment and their opinions on the most promising agents currently in the pipeline.


Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report

Price and Delivery Options
See related reports or call the number above for help from a research specialist.


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2008